DOE OSTI2019
The Office of Radiological Security (ORS) within the U.S. DOE’s National Nuclear Security Administration (NNSA) is charged to “work with government, law enforcement, and businesses across the globe to protect radioactive sources used for medical, research, and commercial purposes; remove and dispose of disused radioactive sources; and reduce the global reliance on high activity radioactive sources through the promotion of viable non-radioisotopic alternative technologies.” In this effort, the NNSA/ORS, along with the Office of Defense Nuclear Nonproliferation R&D, has been working with government and private entities that utilize gamma-ray irradiators in areas that include blood irradiation, radiotherapy, biology research, well logging, and radiation processing to consider alternative technologies that do not depend upon radioactive materials. In the medical device industry, nearly 50% of products are sterilized with ethylene oxide, 40.5% with cobalt-60 gamma-rays, 4.5% with electron-beam (e-beam), and <1% with X-ray.(1,2) The cobalt-60 irradiation facilities use an estimated 150 MCi of isotope to sterilize approximately 200 million cubic feet of product annually.(3) Due to growing safety regulations governing cobalt-60 use, continued advancements in e-beam and X-ray accelerator technology, and the greater irradiation durations and costs for cobalt-60 irradiation compared to e-beam and X-ray, switching to these non-radionuclide modalities is increasingly economically competitive. However, this breakdown of 40.5% cobalt-60 and 5.5% accelerator for product sterilization illustrates the difficulty that market forces and industry players have had in overcoming barriers in transitioning to non-nuclide alternatives. Besides those associated with construction of new e-beam and X-ray facilities, significant financial and regulatory obstacles are also associated with the irradiation and comprehensive testing of product constituent polymers and elastomers. The standards associated with product material performance testing are the Association for the Advancement of Medical Instrumentation (AAMI) Technical Information Report 17 (TIR 17), and its referenced American Society for Testing and Materials (ASTM) polymer testing standards. In the study now underway, and the subject of this article, the NNSA/ORS provided R&D funding to the Pacific Northwest National Laboratory (PNNL) in partnership with university researchers, leading medical product manufacturers, accelerator manufacturers, and contract sterilizers. The resulting Team Nablo (in memory of Sam Nablo) includes individuals representing PNNL, Becton Dickinson (BD), Johnson & Johnson, Stryker, Texas A&M University (TAMU), Steri-Tek, Mevex, Ion Beam Applications (IBA), and Sterigenics. The goals of this study are to 1) Identify specific polymer and/or elastomer-based medical products that are currently sterilized with gamma-rays, and for which there are data gaps and would be of greatest industry impact, 2) Work with relevant ASTM subcommittees for guidance and for potential standard revision, 3) Work with an appropriate Food & Drug Administration (FDA) office for potential collaboration on a guidance document for device manufacturers, 4) Measure the physical effects that product materials exhibit when they are given sterilization-level radiation doses from cobalt-60, e-beam or X-ray, and determine whether these effects would preclude the use of e-beam or X-ray for sterilization, 5) Communicate the resulting scientific datasets and findings via industry conferences, peer-reviewed journals, and relevant trade magazines, and 6) Post the resulting datasets on a publicly accessible website, which can be built on in future years. The end objective is to identify technical barriers preventing the adoption of X-ray and e-beam technologies, and share the results to encourage X-ray and e-beam adoption where feasible.
sterilization, alternate technologies, gamma, X-ra↗